Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.

Revenue
+9.98%
EPS
+29.4%
Free cash flow
+6.21%
Total debt
−2.20%

Quarter to September 2026, against a year earlier

255.90 1.16 +0.46%
Market cap
$28.0B
P/E
25.1×
Fwd P/E
24.4×
Dividend yield
1.32%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

19.56 21.37 22.22 22.89
P/S ratio
1.75 1.91 2.04 2.17
P/FCF ratio
14.17 16.26 17.44 18.65
P/Operating CF
41.42 77.55 39.41 41.96
P/B ratio
2.67 2.81 3.01 3.22
EV/Sales
2.22 2.38 2.47 2.57
EV/EBITDA
11.53 12.27 12.92 13.17
EV/FCF
18.04 20.23 21.16 22.10
Current Ratio
1.04 1.18 1.59 1.70
Net Debt/EBITDA
9.89 9.64 8.29 7.59
Debt/Equity
0.79 0.74 0.72 0.70
Earnings Yield
5.11% 4.68% 4.50% 4.37%
Free Cash Flow Yield
7.06% 6.15% 5.73% 5.36%
Free Cash Flow per Share
2.77 1.49 4.14 4.05
Book value per Share
64.92 69.69 70.44 72.27
Free Cash Flow
307.00 164.00 459.00 445.00
EV/EBIT
15.75 16.67 17.51 17.64
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026